Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20015580 | 1.00 | MAOA (0.52) | MAOAMAOBGPR119MEN1KMT2A | |
| SCHEMBL14261771 | 0.87 | GPR119 (0.51) | GPR119MEN1KMT2AKDM4EPKM | |
| SCHEMBL10068851 | 0.87 | GPR119 (0.51) | GPR119MEN1KMT2AKDM4EPKM | |
| SCHEMBL2721409 | 0.86 | STS (0.52) | GPR119MEN1KMT2AKDM4EPKM | |
| SCHEMBL2721411 | 0.86 | STS (0.52) | GPR119MEN1KMT2AKDM4EPKM | |
| SCHEMBL14261775 | 0.86 | GPR119 (0.50) | GPR119MEN1KMT2AKDM4EPKM | |
| SCHEMBL20015276 | 0.85 | DPP4 (0.53) | MAOAMAOBGPR119MEN1KMT2A | |
| SCHEMBL20015274 | 0.85 | DPP4 (0.53) | MAOAMAOBGPR119MEN1KMT2A | |
| SCHEMBL14261770 | 0.85 | GPR119 (0.49) | GPR119MEN1KMT2AKDM4EPKM | |
| SCHEMBL6011017 | 0.84 | GPR119 (0.48) | GPR119MEN1KMT2AKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018055096-A1 | DISUBTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES AS INHIBITORS OF MONOAMINE OXIDASE B FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIVERSITY OF LJUBLJANA (SI) | 2018-03-29 | — | — | WO | disclosed |
| EP-1785415-B1 | PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20080070898-A1 | Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20080070898-A1 | Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1785415-A1 | PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070898-A1 | Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof | TRPV1, TRPA1, CACNA1D | MAOA 3281/4885MAOB 3198/4885GPR119 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.